



## **Zeltia reports results for the first quarter of 2014**

- **Yondelis<sup>®</sup> net sales increased by 18% (1Q14: 19.7 million euro)**
- **Yondelis<sup>®</sup> attained its highest quarterly commercial sales since reaching market.**
- **Zeltia group EBITDA totalled 19.4 million euro in 1Q 2014 (+10%).**
- **Zeltia group net attributable profit amounted to 16.8 million euro in 1Q 2014 (+6.8%).**
- **Zeltia group reduced its total net debt by 11% since start of the year.**

**Madrid, 29 April 2014.** Zeltia group announces its financial results for the first quarter 2014. Zeltia group's net sales amounted to 34.2 million euro in the first three months of 2014, up 11% with respect to the same period last year. Sales increased in all of the group's business areas. Sales in the Biopharmaceuticals area increased by 16%, reaching almost 21 million euro. Yondelis<sup>®</sup> contributed notably to the group's performance with the drug's best quarterly figures since it reached the market. Sales of Yondelis<sup>®</sup> grew to 19.7 million euro, 18% rise compared to the same period last year. Consumer chemicals revenues totalled 13.1 million euro (+5% year-on-year).

Zeltia group's EBITDA amounted to 19.3 million euro in the first quarter, a 10% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for 21.8 million euro in EBITDA (1Q13: 20.4 million euro).

As a result, Zeltia group's attributable net profit amounted to 16.8 million euro in 1Q14 (1Q13: 15.8 million euro).



During the first quarter, revenue growth in all business areas also boosted operating cash flow to 8.1 million euro, which enabled the group to reduce total net debt by approximately 11% in the first three months of the year.

### **About Zeltia**

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

### **For more information +34 91 444 4500**

This note is also available on the Zeltia web site: [www.zeltia.com](http://www.zeltia.com)